Metacrine Announces Pricing of Initial Public Offering
September 15 2020 - 9:52PM
Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical
company focused on discovering and developing differentiated
therapies for patients with liver and gastrointestinal diseases,
today announced the pricing of its initial public offering of
6,540,000 shares of its common stock at a public offering price of
$13.00 per share. The gross proceeds to Metacrine from the
offering, before deducting underwriting discounts and commissions
and other offering expenses payable by Metacrine, are expected to
be approximately $85.0 million. In addition, Metacrine has granted
the underwriters a 30-day option to purchase up to 981,000
additional shares of its common stock at the initial public
offering price, less the underwriting discounts and commissions.
All of the shares are being offered by Metacrine.
Metacrine has been approved for listing on the Nasdaq Global
Market and is expected to begin trading on Wednesday, September 16,
2020 under the ticker symbol “MTCR.” The offering is expected to
close on Friday, September 18, 2020, subject to customary closing
conditions.
Jefferies, Evercore ISI and RBC Capital Markets are acting as
joint book-running managers for the offering. Canaccord Genuity is
acting as lead manager for the offering.
A registration statement relating to the securities being sold
in this offering was declared effective by the Securities and
Exchange Commission on September 15, 2020. The offering is made
only by means of a prospectus, copies of which may be obtained,
when available, from: Jefferies LLC, Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY
10022, by telephone at (877) 821-7388, or by email at
Prospectus_Department@Jefferies.com; Evercore Group L.L.C.,
Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor,
New York, NY 10055, by telephone at (888) 474-0200, or by email at
ecm.prospectus@evercore.com; or RBC Capital Markets, LLC,
Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York,
NY 10281, by telephone at (877) 822-4089, or by email at
equityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such an
offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About MetacrineMetacrine is a clinical-stage
biopharmaceutical company building a differentiated pipeline of
therapies to treat liver and gastrointestinal (GI) diseases. The
company’s most advanced programs, MET409 and MET642, target the
farnesoid X receptor (FXR), which is central to modulating liver
and GI diseases. Both MET409 and MET642 are currently being
investigated in clinical trials as potential new treatments for
non-alcoholic steatohepatitis (NASH).
Contact:Chelcie Lister THRUST Strategic
Communications910-777-3049investors@metacrine.com
Metacrine (NASDAQ:MTCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Metacrine (NASDAQ:MTCR)
Historical Stock Chart
From Apr 2023 to Apr 2024